Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study highlights how HPV and TP53 molecular subtyping in stage I vulvar squamous cell carcinoma delineates survival outcomes and recurrence risks, supporting its role in personalized management strategies.
MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.
Emerging data from UK clinical trials indicate that while high genomic complexity (HGC) correlates with poor outcomes in CLL, it often serves as a surrogate for other established high-risk markers like TP53 status and telomere length.